We are extremely pleased that Grupo IMO hosted this symposium highlighting the excellent clinical stereotactic work being done by TomoTherapy customers. We are eager to demonstrate how the clinical applications of TomoTherapy continue to grow as new treatment possibilities are explored by our clinical partners.
MADISON, Wis. (PRWEB) October 15, 2008
According to Jef Van Dam, TomoTherapy EMEA General Manager: "We are extremely pleased that Grupo IMO hosted this symposium highlighting the excellent clinical stereotactic work being done by TomoTherapy customers. We are eager to demonstrate how the clinical applications of TomoTherapy continue to grow as new treatment possibilities are explored by our clinical partners."
The 'Symposium on Tomo-Radiosurgery' included presentations from Dr. José Samblás, neurosurgeon and Grupo IMO president, Dr. José Miguel Delgado, clinical physicist and technical director for Grupo IMO, and Dr. Matthias Uhl, radiation oncologist, Heidelberg University Clinic, Heidelberg, Germany. The event was held in conjunction with the Spanish Radiosurgery Conference.
Peter Hoban, Ph.D., TomoTherapy senior product manager and medical physicist, began the program by outlining features that make the Hi·Art system ideal for providing stereotactic treatments: "TomoTherapy's integrated imaging and delivery platform allows one simple process to be used for both stereotactic and intensity-modulated radiation therapy (IMRT) treatments. The system clearly lends itself to a diverse range of clinical indications, as evidenced by the presentations of Drs. Samblás, Delgado and Uhl."
Dr. Samblás and Dr. Delgado presented technical and clinical stereotactic work using the TomoTherapy Hi·Art treatment system and discussed Grupo IMO's research goals for the future.
Said Dr. Samblás: "TomoTherapy Hi·Art allows the development of new techniques for treating brain tumors with maximum precision. In this sense, we have achieved great preliminary results with what we call Tomo-Radiosurgery, fundamentally with regard to irregularly shaped brain tumors, brain metastases and tumors located close to critical organs such as the optic nerves and the brain stem. Another example is the treatment of acoustic neurinoma. We believe TomoTherapy's especially homogenous dose distribution capabilities may help to spare sensitive auditory nerve tissue."
Dr. Matthias Uhl explained how University Clinic Heidelberg has expanded its own use of the TomoTherapy Hi·Art system to include stereotactic treatments.
"We are applying TomoTherapy to SBRT for early-stage lung cancer and also multiple metastases in the brain and liver," said Dr. Uhl. "Treating multiple lesions simultaneously results in a reduced amount of time the patient spends in the treatment room compared with conventional treatment alternatives."
About Grupo IMO
Grupo IMO is the first facility in Spain to offer TomoTherapy® radiation treatments. More than 300 patients have been treated on the TomoTherapy® Hi·Art® System since April 2006. Established in 1991, Grupo IMO has the largest autonomous network of ten reference centers for cancer treatment using radiotherapy and radiosurgery techniques in Spain.
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.
©2008 TomoTherapy Incorporated. All rights reserved. TomoTherapy, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.